JMIR Cardio

JMIR Cardio is an open access journal founded in 2017 and published by JMIR Publications Inc. in Toronto, covering cardiovascular medicine with an emphasis on electronic, mobile and digital health, and its 2025 Journal Impact Factor is 2.4, second quartile in cardiac and cardiovascular systems.《JMIR Cardio》是 2017 年创办的开放获取期刊，由位于多伦多（Toronto）的 JMIR Publications Inc. 出版，关注心血管医学，重点在电子、移动与数字健康路径，2025 年期刊影响因子为 2.4，在心脏与心血管系统类目位列 Q2 区。

Scope

• The focus statement centres on cardiovascular medicine read through health services research, with electronic and mobile health approaches applied to the prevention and treatment of cardiovascular conditions.刊物自述的重心落在心血管医学与卫生服务研究的接合处，电子健康与移动健康手段用于心血管疾病的预防和治疗。

• A subtitle on the homepage frames the same territory from the other side, naming electronic, mobile and digital health approaches in cardiology and for cardiovascular health.首页副题从另一侧圈定同一片领域，点名心脏病学内部的电子、移动与数字健康路径，以及服务心血管健康的同类路径。

• Cardiac Surgery is one of the sections under which the journal files articles, so operative and perioperative work stays inside a cardiovascular medicine title.心脏外科是刊物归档文章的一个栏目，手术与围手术期的工作因此留在心血管医学刊物之内。

• Cardiac Diagnostics covers the tests and measurements by which a cardiac diagnosis is established, with imaging and functional assessment both falling under that heading.心脏诊断栏目覆盖确立心脏诊断所需的检查与测量，影像与功能评估都归在这一名下。

• Cardiac Rehabilitation takes in exercise training programmes, secondary prevention after a cardiac event and supervised recovery delivered outside hospital walls.心脏康复栏目收纳运动训练项目、事件后的二级预防，以及交付于医院之外的监护式康复。

• Cardiac Risk and Cardiac Risk Calculators handles prediction models together with the scoring instruments built from them, including papers that test how those instruments perform in practice.心脏风险与心脏风险计算器栏目处理预测模型以及由模型衍生的评分工具，检验这些工具实际表现的论文也在此列。

• Cardiac Disease Management addresses the long stretch of care after diagnosis, where medication, monitoring and follow-up have to be arranged across primary and specialist settings.心脏疾病管理栏目面向确诊之后的长期照护，药物、监测与随访要在基层与专科之间接续安排。

• e-Cardiology and Telemonitoring in Cardiology is the section closest to the journal's name, carrying remote monitoring, transmitted device data and teleconsultation studies.电子心脏病学与远程监测是离刊名最近的栏目，远程监护、设备数据回传与远程会诊研究都归入此处。

• Cardiovascular Disease Prevention holds population and individual strategies alike, from risk factor control to adherence support delivered through mobile applications.心血管疾病预防栏目同时容纳群体策略与个体策略，从危险因素控制到借助移动应用维持的依从性支持。

• Viewpoints and Proposals admits argument and design without a full empirical study, which suits a field where policy and platform decisions move faster than trials do.观点与提案栏目接收论证和方案，不要求完整的实证研究，适合政策与平台决策跑在试验之前的领域。

• Health services research runs through these sections, asking how access, delivery and organisation of cardiac care change once digital routes are added.卫生服务研究贯穿上述栏目，追问数字路径加入之后，心脏照护的可及性、交付方式与组织形态如何变化。

• The focus and scope page keeps to that single statement instead of listing topics, and closes by restating the open access model and the abstracting services that index the title.关注与范围页面只保留这一段说明，没有铺开主题清单，末尾重申开放获取模式与收录本刊的检索服务。

History

• Volume 1 opened in 2017 under JMIR Publications Inc., and the National Library of Medicine records a Toronto imprint dated from that year.第 1 卷于 2017 年面世，出版方是 JMIR Publications Inc.，美国国家医学图书馆把这一年的出版地记为多伦多（Toronto）。

• PubMed has carried the journal from volume 1, number 1 in 2017, and PubMed Central holds the full text of its articles.PubMed 自 2017 年第 1 卷第 1 期起收录本刊，文章全文由 PubMed Central 保存。

• Full MEDLINE indexing came later and is dated from volume 8 in 2024, so the first seven volumes sat in PubMed without that status.完整的 MEDLINE 收录来得更晚，起点记为 2024 年第 8 卷，前七卷在 PubMed 中没有这一身份。

• Web of Science Core Collection listing came through the editorial criteria route, and the Journal Citation Reports now file the title under the Emerging Sources Citation Index.进入 Web of Science 核心合集走的是编辑标准评估路径，期刊引证报告现把本刊归在新兴来源引文索引（Emerging Sources Citation Index）之下。

• The 2025 Journal Impact Factor is 2.4, up from 2.2 a year earlier, a modest rise that kept the title near the middle of its category.2025 年影响因子为 2.4，比上一年的 2.2 略有上升，位次仍停在类目中段。

• A Journal Citation Indicator of 0.57 puts citation impact close to the field norm, with 597 citations accumulated and a cited half-life of 3.6 years.期刊引证指标为 0.57，引用影响接近领域常态，累计被引 597 次，被引半衰期为 3.6 年。

• Output stays small, at 55 articles in the 2025 count, which fits a specialist title that publishes continuously rather than in thick issues.年发文量保持在较小规模，2025 年计数为 55 篇，与连续出版、不凑厚期的方式相称。

• Scopus gives the journal a CiteScore of 4.9, ranking it 115 of 409 in cardiology and cardiovascular medicine and 72 of 168 in health informatics.Scopus 给出的 CiteScore 为 4.9，在心脏病学与心血管医学类目 409 种刊物中列第 115 位，在健康信息学类目 168 种中列第 72 位。

• Those two ranks, at the 72nd and 57th percentile, describe a journal read on both the clinical and the informatics side of its subject.两个位次分别落在第 72 与第 57 百分位，读者同时来自临床一侧与信息学一侧。

• Publication is continuous, with accepted and copy-edited articles posted as soon as they are ready, and the National Library of Medicine still carries an older semiannual designation.出版方式为连续出版，录用并完成编辑加工的文章随时上线，美国国家医学图书馆的目录里仍留着旧的半年刊标注。

• One volume has been completed each year since 2017, so volume numbering and the calendar year have stayed in step.自 2017 年起每年完成一卷，卷号与日历年始终同步。

• The journal is fully gold open access, with every article under a CC BY licence, and the Directory of Open Access Journals records it in those terms.本刊为完全的黄金开放获取，全部文章采用 CC BY 许可，开放获取期刊目录（DOAJ）的记录与此一致。

• Long-term archiving runs through PubMed Central, and the journal also appears in Scopus, Sherpa Romeo and CABI according to its own listing.长期保存依托 PubMed Central，按刊物自己的列举，本刊还见于 Scopus、Sherpa Romeo 与 CABI。

• The National Library of Medicine catalogues the title in lower case as "JMIR cardio" and uses JMIR Cardio as the Medline abbreviation, so the two forms differ by case alone.美国国家医学图书馆的目录把刊名记作「JMIR cardio」，Medline 缩写则用「JMIR Cardio」，两者只差大小写。

Editors

• Sebastian Spethmann, MD, MHBA, is editor-in-chief and deputy director of the Department of Cardiology, Angiology and Intensive Care Medicine at the German Heart Center at Charité in Berlin.现任主编是（Sebastian Spethmann），他在柏林 Charité 大学医学中心德国心脏中心（Deutsches Herzzentrum der Charité）任心脏病学、血管病学与重症医学科副主任。

• His clinical work covers heart failure, cardiomyopathy, structural heart disease and cardiovascular imaging, and he co-speaks the Amyloidosis Centre Berlin Charité.他的临床方向包括心力衰竭、心肌病、结构性心脏病与心血管影像，同时担任柏林 Charité 淀粉样变中心（Amyloidosis Centre Berlin Charité）的联合发言人。

• On the research side he works on putting innovation into practice, access to care, digital cardiology and telemedicine, health services research and amyloidosis.研究一侧，他关注创新落地、就医可及性、数字心脏病学与远程医疗、卫生服务研究以及淀粉样变。

• Aidan Thompson is the managing editor named on the board page, the only editorial post listed between the editor-in-chief and the associate editors.（Aidan Thompson）任执行编辑，编委页上主编与副编辑之间只有这一个编辑职位。

• Nine associate editors handle manuscripts, four of them based in Europe: Goran Krstačić in Zagreb, Felix Muehlensiepen in Germany, Paweł Krzesiński in Poland and Sara Vázquez-Calvo in Spain.九位副编辑分担稿件，其中四位在欧洲，即萨格勒布的（Goran Krstačić）、德国的（Felix Muehlensiepen）、波兰的（Paweł Krzesiński）与西班牙的（Sara Vázquez-Calvo）。

• Krstačić works at the Institute for Cardiovascular Prevention and Rehabilitation in Zagreb, which gives the rehabilitation section an editor with a matching brief.（Goran Krstačić）任职于萨格勒布的心血管预防与康复研究所（Institute for Cardiovascular Prevention and Rehabilitation），康复栏目因此有一位方向相近的编辑。

• The other five sit outside Europe: Nitesh Ainani at Tidelands Health and MUSC Health in the United States, John T. Rivers and Kam Cheong Wong in Australia, Avik Ray in India and Aniruddha Singh in the United States.另外五位在欧洲之外，（Nitesh Ainani）在美国的 Tidelands Health 与 MUSC Health 任职，（John T. Rivers）与（Kam Cheong Wong）在澳大利亚，（Avik Ray）在印度，（Aniruddha Singh）在美国。

• Eight members sit on the editorial board, among them Ponrathi Athilingam, Ruben Casado Arroyo, Paul Cummins, Vasundhara Muthu and Aaron Peace.编委会另有八位成员，包括（Ponrathi Athilingam）、（Ruben Casado Arroyo）、（Paul Cummins）、（Vasundhara Muthu）与（Aaron Peace）。

• The remaining three are Andrew J. Coristine, Ivan Steenstra and Nico Bruining, whose entry carries the label Former Editor-in-Chief without a term of office.其余三位是（Andrew J. Coristine）、（Ivan Steenstra）与（Nico Bruining），后者的条目标注为前任主编，页面没有给出任期。

• Every manuscript is first checked against the formal criteria and the scope, and the handling editor consults board members when the fit is unclear.每篇稿件先过形式要件与范围两道检查，归属不清时由处理编辑征询编委意见。

• A manuscript then goes to an associate editor and to two to four external experts, and the associate editor decides on the reviewed text while the editor-in-chief takes the final call on acceptance.稿件随后交给一位副编辑与两到四位外部专家，副编辑依据评审结果作出编辑决定，录用的最终裁定权在主编。

• Review is single-anonymized, so reviewers know who wrote the paper while their own names are printed at the end of the article once it appears.评审采用单向匿名，评审人知道作者是谁，评审人自己的名字则在文章发表时印在文末。

• Authors must suggest at least two potential reviewers without a conflict of interest, and every author needs an ORCID at the point of publication.作者投稿时须推荐至少两位没有利益冲突的评审人，全体作者在发表时须持有 ORCID。

• A fast track promises an editorial decision within 20 business days and publication within four weeks of acceptance, while standard submissions get averages only.快速通道承诺 20 个工作日内给出编辑决定，录用后四周内发表，普通稿件只给平均周期，不作保证。

• Preprints may be submitted if the earlier posting is disclosed, a content overlap of ten percent can count as duplicative, and public preprint review windows are posted on the homepage.预印本在披露的前提下可以投稿，正文重合度达到一成即可能被判为重复投稿，首页还挂出公开的预印本评审窗口。